Lagarde Sjoerd M, Anderegg Martinus C J, Gisbertz Suzanne S, Meijer Sybren L, Hulshof Maarten C C M, Bergman Jacques J G H M, van Laarhoven Hanneke W M, van Berge Henegouwen Mark I
Department of Surgery, Academic Medical Center, Amsterdam, the Netherlands.
Department of Pathology, Academic Medical Center, Amsterdam, the Netherlands.
J Thorac Dis. 2018 Mar;10(3):1511-1521. doi: 10.21037/jtd.2018.02.81.
The aim of the present study is to identify the incidence and prognostic significance of lymph node metastases near the celiac trunk in patients who underwent neoadjuvant chemo(radio)therapy followed by esophagectomy.
Between March 1994 and September 2013 a total of 462 consecutive patients with cancer of the esophagus or gastroesophageal junction (GEJ) who underwent potentially curative esophageal resection after neoadjuvant chemotherapy (N=88; 19.0%) or neoadjuvant chemoradiotherapy (CRT) (N=374; 81.0%) were included.
Seventy one (15.4%) patients had truncal node metastases in the resection specimen. Metastases to these nodes occurred more frequently in male patients with adenocarcinoma and in tumors at the gastro-esophageal junction. A lower response to neoadjuvant treatment, higher ypT and ypN stages and a poorer grade of differentiation were significantly related with truncal node metastases. Patients with tumor positive truncal nodes had a worse median overall survival (17 55 months). In multivariate analysis, truncal node metastases were independently associated with a worse survival. Only 22 (31.0%) of the 71 patients with tumor positive truncal nodes were identified preoperatively with EUS or CT. In contrast, 37 patients had suspicious truncal nodes on EUS or CT, but metastases in the pathology specimen were absent.
In the present study, it is demonstrated that positive truncal nodes in the resection specimen after neoadjuvant therapy, are associated with advanced tumor stages and are an independent factor for inferior survival.
本研究的目的是确定接受新辅助化疗(放疗)后行食管切除术的患者腹腔干周围淋巴结转移的发生率及预后意义。
纳入1994年3月至2013年9月期间连续462例接受新辅助化疗(n = 88;19.0%)或新辅助放化疗(CRT)(n = 374;81.0%)后行根治性食管切除术的食管癌或胃食管交界(GEJ)癌患者。
71例(15.4%)患者切除标本中存在腹腔干周围淋巴结转移。这些淋巴结转移在腺癌男性患者及胃食管交界部肿瘤中更常见。新辅助治疗反应较低、ypT和ypN分期较高以及分化程度较差与腹腔干周围淋巴结转移显著相关。腹腔干周围淋巴结阳性的患者中位总生存期较差(17.55个月)。多因素分析显示,腹腔干周围淋巴结转移与较差的生存率独立相关。71例腹腔干周围淋巴结阳性患者中,术前仅22例(31.0%)通过超声内镜(EUS)或CT检查发现。相反,37例患者EUS或CT检查显示腹腔干周围淋巴结可疑,但病理标本中无转移。
本研究表明,新辅助治疗后切除标本中腹腔干周围淋巴结阳性与肿瘤晚期相关,是生存较差的独立因素。